Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Colleague Insights
Grand Rounds
Conferences
Video Expert Opinion
Living Resources
Sign in
Join now
story of the week
Published in Obesity, Metabolic Syndrome, and Prediabetes and
2 other channels

Journal Scan / Research · July 08, 2021

Tirzepatide vs Semaglutide in Patients With Type 2 Diabetes

The New England Journal of Medicine

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Vanita Aroda MD

The New England Journal of Medicine
Tirzepatide Versus Semaglutide Once Weekly in Patients With Type 2 Diabetes
N. Engl. J. Med 2021 Jun 25;[EPub Ahead of Print], JP Frías, MJ Davies, J Rosenstock, FC Pérez Manghi, L Fernández Landó, BK Bergman, B Liu, X Cui, K Brown

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated